

## INFLAMMATORY PARAMETERS ANALYSIS IN SEVERE COVID-19 PATIENTS TREATED WITH TOCILIZUMAB

C. DEL POZO CARLAVILLA<sup>1</sup>, M. CLEMENTE ANDÚJAR<sup>1</sup>, S. PLATA PANIAGUA<sup>1</sup>, M. DEL POZO CARLAVILLA<sup>2</sup>, <u>S. RUIZ SÁNCHEZ<sup>1</sup></u>, B. SERNA SERRANO<sup>1</sup>, C.S. JUAN MANUEL<sup>1</sup>, E. TEBAR MARTÍNEZ<sup>1</sup>, H. ALABORT AYLLÓN<sup>1</sup>, M. SÁEZ GARRIDO<sup>1</sup>. <sup>1</sup>COMPLEJO HOSPITALARIO DE ALBACETE, HOSPITAL PHARMACY, ALBACETE, SPAIN. <sup>2</sup>COMPLEJO HOSPITALARIO DE ALBACETE, PAEDIATRICS, ALBACETE, SPAIN.

## OBJETIVE

The main objective is to evaluate TCZ effectiveness in the modification of inflammatory parameters in severe COVID-19 patients.

MATERIALS AND METHODS	Study variables:
Retrospective observational study patients suffering from COVID-19 admitted at an intensive care unit (ICU) and treated with TCZ from 20 <sup>th</sup> March to 20 <sup>th</sup> May 2020 at a tertiary hospital.	Age
	Sex IL-6 levels
	C-Reactive Protein (CRP)
	Ferritin
	Lymphocytes count
	D-dimer
	Days at ICU
	Deaths
	Patients evolution

## RESULTS

IL-6 levels on day 0 were 293 pg./ml, peaking at 416 pc/ml on day 3 and decreasing to 241.9 pc/ml on day 7<sup>th</sup>.

**CRP levels** raised above the normal range (median 53.35 mg/L on day 0) in all patients before initiation of therapy with TCZ and decreased at day 7<sup>th</sup> (median 3 mg/L).

Serum ferritin decreased from 1798 mg/L on first day to 1197.5 mg/L seventh day of before TCZ.

Lymphocytes count increased from 570 to 1365 lymphocytes/µL on day 7.

D-dimer level on day 0 was 2008 ng/ml and increased to 3910 ng/ml seventh. Day 14<sup>th</sup> it decreased to 1723 ng/ml.

Length in ICU stay was 16.4 days compared to the mean stay of the total number of ICU COVID patients, which was 26.1 days. Patient's mortality was 19.6%, 15.2% remained interned at the end of the study and 65.2% were discharged.

## CONCLUSIONS

Results show an improvement in inflammatory markers with TCZ treatment, as well as a decrease in length in ICU stay, similar findings have been reported in consulted bibliography.

Nevertheless, due to potential bias: patients received different treatments before and after TCZ and the small sample size, it is necessary to confirm these results with controlled clinical essays.